My Companies
Notification
Account
Log Out
Login
Acquired 100% equity in MicroBiopharm Japan Co Ltd from T Capital Partners funds for JPY 21.5bn via wholly owned Themis Biosyn Japan, fermentation APIs/CDMO maker with FY26 revenue JPY 9.5bn. Context: closes pending MBJ acquisition, largest to date.
Gujarat Themis Biosyn Allots Rs 585 Crore NCDs To Fund MBJ Acquisition
Gujarat Themis Biosyn Approves ₹585 Crore Unlisted NCD Programme
Gujarat Themis Biosyn Board Approves ₹335 Crore Preferential Share Issue
Gujarat Themis Biosyn Closes ₹750 Crore QIP At ₹354 Per Share
Gujarat Themis Biosyn Opens QIP At ₹372.57 Floor Price